Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.

Abstract

The μ-bcr breakpoint connects exon 19 of BCR with ABL giving rise to the e19a2 transcript corresponding to the p230 fusion protein (micro-BCR breakpoint) which is rarely seen in chronic myeloid leukemia (CML) patients. Here we report three patients with p230 fusion protein presenting with different clinical presentations and diagnosed as CML-CP. These patients received Imatinib (tyrosine kinase inhibitor-TKI) and are still in remission.

• Authors: Sudha Sazawal, Sunita Chikkara, Kanwaljeet Singh, Rekha Chaubey, Dinesh Chandra, Pravas Mishra, Manoranjan Mahapatra, Tulika Seth, Renu Saxena
• Journal: Annals of diagnostic pathology (Ann Diagn Pathol) Vol. 27 Pg. 24-27 (Apr 2017) ISSN: 1532-8198 [Electronic] United States
• PMID: 28325357 (Publication Type: Case Reports, Letter)
• Copyright: Copyright © 2016 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents
• BCR-ABL1 fusion protein, human
• Imatinib Mesylate
• Fusion Proteins, bcr-abl

Topics

• Adult
• Antineoplastic Agents (therapeutic use)
• Female
• Fusion Proteins, bcr-abl (genetics)
• Humans
• Imatinib Mesylate (therapeutic use)
• India
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (diagnosis, drug therapy, pathology)
• Male
• Middle Aged
• Transcription, Genetic
• Treatment Outcome